The broad eligibility criteria of the recently EMA approved triple combination elexafactor-tezacaftor-ivacaftor [11, 12], significantly expanded the group of eligible patients after the age of 12 years for CFTR modulator therapy to up to 66% of the total CF population in Cyprus. Here, CFTR is linked to cystic fibrosis.